Relevance of Reversible Causes During OHCA (Rebecca Study)
Launched by MEDICAL UNIVERSITY OF VIENNA · Mar 13, 2023
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
The Rebecca Study is looking at how to improve the treatment of patients who experience cardiac arrest outside of a hospital. During such emergencies, it's important to identify any reversible causes—like heart rhythm problems or intoxication—that could be treated to help save lives. The study will use special tools, like ultrasound and blood tests, to quickly find these causes. Researchers will also assess how well doctors perform CPR and how demanding the situation is for them while they try to save a patient. In total, they plan to include 100 patients who have had a cardiac arrest.
To be eligible for this study, patients must be 18 years or older and have experienced a cardiac arrest where doctors can quickly use these diagnostic tools without delaying necessary life-saving care. Pregnant women will not be included in the study. Participants can expect to contribute to important research that aims to make emergency cardiac care more effective, potentially leading to better outcomes for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with prehospital cardiac arrest, where POCUS, blood gas analysis as well as screening for intoxication can integrated in ALS rhythm without delay of life-saving treatment or transportation will be included.
- Exclusion Criteria:
- • Patients will be excluded under the age of 18, or if POCUS, blood gas analysis will lead to a delay of live-saving treatment or transportation. Furthermore, pregnant patients will be excluded.
About Medical University Of Vienna
The Medical University of Vienna is a leading research institution dedicated to advancing healthcare through innovative clinical research and education. Renowned for its commitment to excellence in medical science, the university fosters interdisciplinary collaboration among researchers, clinicians, and academic professionals. Its clinical trials encompass a wide range of medical disciplines, aiming to develop cutting-edge therapies and improve patient outcomes. With state-of-the-art facilities and a strong emphasis on ethical standards, the Medical University of Vienna is at the forefront of transforming scientific discoveries into practical applications that enhance global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Vienna, , Austria
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials